Development of Low-Grade Serous Ovarian Carcinoma from Benign Ovarian Serous Cystadenoma Cells.
KRAS
PIK3CA
carcinogenesis
low-grade serous ovarian carcinoma
ovarian cancer
ovarian serous cystadenoma
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
15 Mar 2022
15 Mar 2022
Historique:
received:
01
02
2022
revised:
09
03
2022
accepted:
12
03
2022
entrez:
25
3
2022
pubmed:
26
3
2022
medline:
26
3
2022
Statut:
epublish
Résumé
Despite the knowledge about numerous genetic mutations essential for the progression of low-grade serous ovarian carcinoma (LGSOC), the specific combination of mutations required remains unclear. Here, we aimed to recognize the oncogenic mutations responsible for the stepwise development of LGSOC using immortalized HOVs-cyst-1 cells, developed from ovarian serous cystadenoma cells, and immortalized via
Identifiants
pubmed: 35326657
pii: cancers14061506
doi: 10.3390/cancers14061506
pmc: PMC8946187
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Proc Natl Acad Sci U S A. 2009 Mar 24;106(12):4828-33
pubmed: 19261858
Proc Natl Acad Sci U S A. 2015 Jan 6;112(1):118-23
pubmed: 25535351
Br J Cancer. 2012 Mar 13;106(6):1205-13
pubmed: 22353808
Cancer Biol Ther. 2006 Jul;5(7):779-85
pubmed: 16721043
Cancer Res. 2013 Jun 1;73(11):3248-61
pubmed: 23580570
Oncol Rep. 2001 Nov-Dec;8(6):1285-7
pubmed: 11605050
Gene Ther. 2011 Sep;18(9):857-66
pubmed: 21490680
Crit Rev Oncol Hematol. 2015 Apr;94(1):18-30
pubmed: 25591826
Lab Invest. 2004 Jun;84(6):778-84
pubmed: 15077125
Am J Pathol. 2004 May;164(5):1511-8
pubmed: 15111296
Cancers (Basel). 2021 Jun 25;13(13):
pubmed: 34202354
Int J Mol Sci. 2016 Apr 26;17(5):
pubmed: 27128903
Onco Targets Ther. 2014 Oct 16;7:1891-9
pubmed: 25342912
Gynecol Oncol. 2012 Jun;125(3):661-6
pubmed: 22406638
Cancer Biol Ther. 2012 Mar;13(5):296-306
pubmed: 22258036
Gynecol Oncol. 2019 Sep;154(3):531-538
pubmed: 31227223
Am J Pathol. 2010 Oct;177(4):1611-7
pubmed: 20802181
Am J Surg Pathol. 2004 Apr;28(4):496-504
pubmed: 15087669
Science. 1995 Sep 1;269(5228):1281-4
pubmed: 7652577
N Engl J Med. 2015 Nov 12;373(20):1895-8
pubmed: 26559569
J Pathol. 2012 Feb;226(3):413-20
pubmed: 22102435
Nature. 2011 Jun 29;474(7353):609-15
pubmed: 21720365
Diagnostics (Basel). 2019 Dec 27;10(1):
pubmed: 31892193
Diagnostics (Basel). 2020 Apr 03;10(4):
pubmed: 32260152
Appl Immunohistochem Mol Morphol. 2015 Apr;23(4):280-7
pubmed: 24992169
Int J Gynecol Cancer. 2007 May-Jun;17(3):601-6
pubmed: 17504374
Carcinogenesis. 2010 Jan;31(1):27-36
pubmed: 19752007
J Virol. 1998 Oct;72(10):8150-7
pubmed: 9733856
Am J Pathol. 2002 Apr;160(4):1223-8
pubmed: 11943707
Oncotarget. 2017 Dec 8;9(16):12609-12619
pubmed: 29560094
Am J Surg Pathol. 2010 May;34(5):627-35
pubmed: 20414098
Carcinogenesis. 2009 Mar;30(3):423-31
pubmed: 19126650
Cancer Res. 2017 Aug 15;77(16):4268-4278
pubmed: 28646021
Gynecol Oncol. 2013 Feb;128(2):371-6
pubmed: 23103384
Cancer. 2013 Feb 1;119(3):548-554
pubmed: 22930283
Gynecol Oncol. 2017 Oct;147(1):85-91
pubmed: 28768570
Oncotarget. 2015 Nov 10;6(35):37663-77
pubmed: 26506417
Nat Genet. 2020 Jul;52(7):709-718
pubmed: 32601473